NCT07901179
A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Incidence of treatment-emergent adverse events
Timeframe: Up to 8 weeks
Secondary (2)
Change from Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score
Change in Baseline to Week 6 in Clinical Global Impression-Severity (CGI-S)
Arms and interventions
ALKS 7290 and Antidepressant TherapyExperimental
Placebo and Antidepressant TherapyPlacebo comparator
Drugs: ALKS 7290 Dose, Placebo
Sites
1 site in 1 country
- Alkermes Investigator SiteJacksonville, Florida, United States